Agios Pharmaceuticals, Inc. (AGIO) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
30Y Low57.0·High57.0
P/B Ratio
↓
1.31
-7% vs avg
5yr avg: 1.40
30Y Low1.2·High8.9
ROE
↓
-30.2%
↑-194% vs avg
5yr avg: 32.1%
30Y Low-86%·High190%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
AGIO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Agios Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.6B | $1.6B | $1.9B | $1.2B | $1.5B | $2.0B | $3.0B | $2.9B | $2.6B | $2.7B | $1.6B |
| Enterprise Value | $1.6B | $1.6B | $1.9B | $1.2B | $1.5B | $1.9B | $3.0B | $2.9B | $1.8B | $2.1B | $1.1B |
| P/E Ratio → | -3.79 | — | 2.82 | — | — | — | — | — | — | — | — |
| P/S Ratio | 29.70 | 29.21 | 52.12 | 46.21 | 108.04 | — | — | 24.30 | 28.05 | 61.92 | 23.36 |
| P/B Ratio | 1.31 | 1.32 | 1.23 | 1.53 | 1.40 | 1.54 | 7.48 | 4.47 | 3.85 | 7.09 | 4.55 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | 57.00 |
| P/OCF | — | — | — | — | — | — | — | — | — | — | 42.34 |
P/E links to full P/E history page with 30-year chart
AGIO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 28.71 | 51.59 | 45.60 | 104.28 | — | — | 24.57 | 19.52 | 48.72 | 15.15 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | 36.97 |
AGIO Profitability
Margins and return-on-capital ratios measuring operating efficiency
Agios Pharmaceuticals, Inc. earns an operating margin of -873.9%. Operating margins have expanded from -1459.5% to -873.9% over the past 3 years, signaling improving operational efficiency. A negative ROE of -30.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.7% | 78.7% | 88.6% | 64.6% | 88.0% | — | — | 98.9% | 98.5% | -580.5% | -215.0% |
| Operating Margin | -873.9% | -873.9% | -1166.5% | -1459.5% | -2732.1% | — | — | -361.6% | -384.0% | -745.8% | -287.6% |
| Net Profit Margin | -764.0% | -764.0% | 1845.9% | -1312.6% | -1627.8% | — | — | -349.0% | -366.6% | -731.6% | -284.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -30.2% | -30.2% | 57.3% | -36.8% | -19.4% | 189.7% | -63.0% | -62.0% | -65.1% | -85.7% | -56.4% |
| ROA | -27.9% | -27.9% | 51.8% | -32.4% | -17.3% | 140.1% | -37.5% | -47.0% | -47.0% | -51.0% | -38.2% |
| ROIC | -26.3% | -26.3% | -27.6% | -31.9% | -26.1% | -36.3% | -48.0% | -115.1% | — | — | — |
| ROCE | -33.8% | -33.8% | -34.7% | -38.3% | -30.5% | -35.4% | -43.2% | -54.6% | -56.4% | -61.1% | -44.8% |
AGIO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $89M exceeds total debt of $62M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.04 | 0.09 | 0.08 | 0.08 | 0.26 | 0.18 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.02 | -0.01 | -0.02 | -0.05 | -0.08 | -0.06 | 0.05 | -1.17 | -1.51 | -1.60 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | -20.02 |
| Interest Coverage | — | — | — | — | — | — | -18.47 | — | — | — | — |
Net cash position: cash ($89M) exceeds total debt ($62M)
AGIO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Agios Pharmaceuticals, Inc.'s current ratio of 11.46x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 11.06x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 12.27x to 11.46x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.46 | 11.46 | 11.90 | 12.27 | 13.30 | 17.79 | 6.74 | 6.59 | 6.56 | 4.69 | 6.33 |
| Quick Ratio | 11.06 | 11.06 | 11.56 | 11.99 | 13.16 | 17.79 | 6.74 | 6.51 | 6.55 | 6.20 | 6.70 |
| Cash Ratio | 10.39 | 10.39 | 11.01 | 11.43 | 12.50 | 17.05 | 6.07 | 6.08 | 8.61 | 5.98 | 6.49 |
| Asset Turnover | — | 0.04 | 0.02 | 0.03 | 0.01 | — | — | 0.13 | 0.11 | 0.07 | 0.11 |
| Inventory Turnover | 0.35 | 0.35 | 0.15 | 0.50 | 0.20 | — | — | 0.18 | 1.61 | — | — |
| Days Sales Outstanding | — | 71.46 | 41.09 | 38.24 | 56.54 | — | — | 47.42 | 40.38 | 31.14 | 43.42 |
AGIO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Agios Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 35.4% | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | 1.8% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 40.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 40.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $58M | $58M | $56M | $55M | $60M | $69M | $60M | $57M | $47M | $39M |
Peer Comparison
Compare AGIO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 AGIOYou | $2B | -3.8 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 IONS | $13B | -32.3 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 PTCT | $6B | 8.6 | 5.6 | 7.9 | 95.9% | 49.5% | — | — | 0.5 |
 RARE | $3B | -4.4 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $4B | -80.5 | 140.6 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
 IMVT | $6B | -10.5 | — | — | — | — | -62.5% | — | — |
 RYTM | $7B | -31.1 | — | — | 89.7% | -101.2% | -129.5% | -70.1% | — |
 SRPT | $2B | -3.2 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 BMRN | $11B | 30.3 | 16.0 | 14.5 | 77.1% | 16.6% | 5.9% | 7.4% | 1.0 |
 ALNY | $40B | 130.0 | 71.9 | 86.9 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 KRYS | $9B | 42.2 | 47.8 | 45.1 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
See AGIO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AGIO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AGIO vs IONS
Side-by-side business, growth, and profitability comparison vs Ionis Pharmaceuticals, Inc..
Start ComparisonAGIO — Frequently Asked Questions
Quick answers to the most common questions about buying AGIO stock.
What is Agios Pharmaceuticals, Inc.'s P/E ratio?
Agios Pharmaceuticals, Inc.'s current P/E ratio is -3.8x. The historical average is 2.8x.
What is Agios Pharmaceuticals, Inc.'s ROE?
Agios Pharmaceuticals, Inc.'s return on equity (ROE) is -30.2%. The historical average is -22.8%.
Is AGIO stock overvalued?
Based on historical data, Agios Pharmaceuticals, Inc. is trading at a P/E of -3.8x. Compare with industry peers and growth rates for a complete picture.
What are Agios Pharmaceuticals, Inc.'s profit margins?
Agios Pharmaceuticals, Inc. has 78.7% gross margin and -873.9% operating margin.